Antibody landscape of C57BL/6 mice cured of B78 melanoma via immunotherapy

Hoefges et al. utilized a whole-proteome peptide array approach to show that C57BL/6 mice develop a large repertoire of antibodies against linear peptide sequences of their melanoma after receiving a curative immunotherapy regimen consisting of radiation and an immunocytokine. Antibodies can play an...

Full description

Saved in:
Bibliographic Details
Published inbioRxiv : the preprint server for biology
Main Authors Hoefges, A, McIlwain, S J, Erbe, A K, Mathers, N, Xu, A, Melby, D, Tetreault, K, Le, T, Kim, K, Pinapati, R S, Garcia, B, Patel, J, Heck, M, Feils, A S, Tsarovsky, N, Hank, J A, Morris, Z S, Ong, I M, Sondel, P M
Format Journal Article
LanguageEnglish
Published United States 28.04.2023
Subjects
antibody
radio-immunotherapy
in situ vaccine
high-density peptide array
melanoma
cancer
proteome
Online AccessGet more information

Cover

More Information
Summary:Hoefges et al. utilized a whole-proteome peptide array approach to show that C57BL/6 mice develop a large repertoire of antibodies against linear peptide sequences of their melanoma after receiving a curative immunotherapy regimen consisting of radiation and an immunocytokine. Antibodies can play an important role in innate and adaptive immune responses against cancer, and in preventing infectious disease. Flow cytometry analysis of sera of immune mice that were previously cured of their melanoma through a combined immunotherapy regimen with long-term memory showed strong antibody-binding against melanoma tumor cell lines. Using a high-density whole-proteome peptide array, we assessed potential protein-targets for antibodies found in immune sera. Sera from 6 of these cured mice were analyzed with this high-density, whole-proteome peptide array to determine specific antibody-binding sites and their linear peptide sequence. We identified thousands of peptides that were targeted by 2 or more of these 6 mice and exhibited strong antibody binding only by immune, not naive sera. Confirmatory studies were done to validate these results using 2 separate ELISA-based systems. To the best of our knowledge, this is the first study of the "immunome" of protein-based epitopes that are recognized by immune sera from mice cured of cancer via immunotherapy.